Globus Medical
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral… Read more
Globus Medical (GMED) - Net Assets
Latest net assets as of September 2025: $4.40 Billion USD
Based on the latest financial reports, Globus Medical (GMED) has net assets worth $4.40 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.10 Billion) and total liabilities ($696.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.40 Billion |
| % of Total Assets | 86.33% |
| Annual Growth Rate | 23.08% |
| 5-Year Change | 177.32% |
| 10-Year Change | 483.98% |
| Growth Volatility | 26.61 |
Globus Medical - Net Assets Trend (2010–2024)
This chart illustrates how Globus Medical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Globus Medical (2010–2024)
The table below shows the annual net assets of Globus Medical from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.18 Billion | +4.49% |
| 2023-12-31 | $4.00 Billion | +116.53% |
| 2022-12-31 | $1.85 Billion | +6.03% |
| 2021-12-31 | $1.74 Billion | +15.61% |
| 2020-12-31 | $1.51 Billion | +7.40% |
| 2019-12-31 | $1.40 Billion | +18.30% |
| 2018-12-31 | $1.19 Billion | +22.50% |
| 2017-12-31 | $967.78 Million | +16.31% |
| 2016-12-31 | $832.08 Million | +16.32% |
| 2015-12-31 | $715.32 Million | +22.18% |
| 2014-12-31 | $585.45 Million | +23.94% |
| 2013-12-31 | $472.36 Million | +22.21% |
| 2012-12-31 | $386.50 Million | +36.83% |
| 2011-12-31 | $282.48 Million | +23.79% |
| 2010-12-31 | $228.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Globus Medical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 814.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.15 Billion | 27.60% |
| Common Stock | $137.00K | 0.00% |
| Other Comprehensive Income | $-6.86 Million | -0.16% |
| Other Components | $3.03 Billion | 72.56% |
| Total Equity | $4.18 Billion | 100.00% |
Globus Medical Competitors by Market Cap
The table below lists competitors of Globus Medical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Toray Industries Inc
PINK:TRYIF
|
$9.58 Billion |
|
Tingyi (Cayman Islands) Holding Corp
PINK:TYCMY
|
$9.58 Billion |
|
Everest Group Ltd
NYSE:EG
|
$9.59 Billion |
|
Applied Industrial Technologies Inc.
LSE:0HGR
|
$9.59 Billion |
|
Anhui Jianghuai Automobile Group Corp Ltd
SHG:600418
|
$9.56 Billion |
|
Eurobank Ergasias Services and Holdings S.A
PINK:EGFEF
|
$9.55 Billion |
|
Scentre Group
PINK:STGPF
|
$9.55 Billion |
|
MPI Corporation
TWO:6223
|
$9.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Globus Medical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,997,959,000 to 4,177,333,000, a change of 179,374,000 (4.5%).
- Net income of 102,984,000 contributed positively to equity growth.
- Share repurchases of 85,787,000 reduced equity.
- Other comprehensive income increased equity by 3,331,000.
- Other factors increased equity by 158,846,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $102.98 Million | +2.47% |
| Share Repurchases | $85.79 Million | -2.05% |
| Other Comprehensive Income | $3.33 Million | +0.08% |
| Other Changes | $158.85 Million | +3.8% |
| Total Change | $- | 4.49% |
Book Value vs Market Value Analysis
This analysis compares Globus Medical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.86x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 28.63x to 2.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $3.02 | $86.58 | x |
| 2011-12-31 | $3.74 | $86.58 | x |
| 2012-12-31 | $4.19 | $86.58 | x |
| 2013-12-31 | $5.01 | $86.58 | x |
| 2014-12-31 | $6.13 | $86.58 | x |
| 2015-12-31 | $7.45 | $86.58 | x |
| 2016-12-31 | $8.63 | $86.58 | x |
| 2017-12-31 | $9.89 | $86.58 | x |
| 2018-12-31 | $11.70 | $86.58 | x |
| 2019-12-31 | $13.75 | $86.58 | x |
| 2020-12-31 | $14.92 | $86.58 | x |
| 2021-12-31 | $16.81 | $86.58 | x |
| 2022-12-31 | $17.99 | $86.58 | x |
| 2023-12-31 | $34.88 | $86.58 | x |
| 2024-12-31 | $30.30 | $86.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Globus Medical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.09%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.26x
- Recent ROE (2.47%) is below the historical average (12.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 23.86% | 18.90% | 1.08x | 1.17x | $31.64 Million |
| 2011 | 21.52% | 18.34% | 1.01x | 1.17x | $32.54 Million |
| 2012 | 19.10% | 19.13% | 0.86x | 1.16x | $35.18 Million |
| 2013 | 14.53% | 15.79% | 0.77x | 1.20x | $21.38 Million |
| 2014 | 15.80% | 19.50% | 0.67x | 1.20x | $33.94 Million |
| 2015 | 15.77% | 20.70% | 0.65x | 1.17x | $41.25 Million |
| 2016 | 12.54% | 18.50% | 0.61x | 1.11x | $21.13 Million |
| 2017 | 11.09% | 16.88% | 0.59x | 1.11x | $10.57 Million |
| 2018 | 13.20% | 21.95% | 0.55x | 1.10x | $37.92 Million |
| 2019 | 11.07% | 19.76% | 0.51x | 1.09x | $14.96 Million |
| 2020 | 6.79% | 12.96% | 0.47x | 1.11x | $-48.34 Million |
| 2021 | 8.57% | 15.57% | 0.49x | 1.12x | $-24.95 Million |
| 2022 | 10.30% | 18.59% | 0.49x | 1.12x | $5.53 Million |
| 2023 | 3.07% | 7.83% | 0.31x | 1.27x | $-276.92 Million |
| 2024 | 2.47% | 4.09% | 0.48x | 1.26x | $-314.75 Million |
Industry Comparison
This section compares Globus Medical's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $498,972,584
- Average return on equity (ROE) among peers: -54.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Globus Medical (GMED) | $4.40 Billion | 23.86% | 0.16x | $9.57 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-2.23 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $187.53 Billion |
| Acarix AB (publ) (ACIXF) | $51.88 Million | -150.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $3.82 Million |
| Adm Tronics Unltd (ADMT) | $644.00K | 0.00% | 0.66x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $6.03 Million | -94.15% | 0.22x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $732.88K |
| Adapthealth Corp (AHCO) | $24.31K | -2.84% | 11.78x | $916.00 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $8.41 Million |